Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last?
Search for other papers by Yvonne A. Efebera in
Current site
Google Scholar
PubMed
Search for other papers by Nina Shah in
Current site
Google Scholar
PubMed
The number of approved regimens for multiple myeloma has increased dramatically in recent years, improving progression-free and overall survival while also increasing the complexity of treatment decisions. Despite the plethora of options available, one fundamental treatment question remains: How long should initial therapy last? At the NCCN 2019 Annual Congress: Hematologic Malignancies, Drs. Yvonne A. Efebera and Nina Shah debated whether myeloma therapy should be time-limited or continue until disease progression.
Disclosures: Dr. Efebera has disclosed that she receives honoraria from Janssen Pharmaceutica Products, LP, and Takeda Pharmaceuticals North America, Inc.; and that she is a scientific advisor for Akcea Therapeutics. Dr. Shah has disclosed that she receives grant/research support from Celgene Corporation, Janssen Pharmaceutica Products, LP, bluebird bio, and Sutro Biopharma, Inc.; owns stock in Indapta Therapeutics; and is a scientific advisor for Genentech, Inc., Seattle Genetics, Inc., Oncopeptides, Karyopharm Therapeutics Inc., Surface Oncology, Precision BioSciences, Inc., GlaxoSmithKline, Nektar Therapeutics, Indapta Therapeutics, and sanofi-aventis U.S. LLC. Dr. Zelenetz has disclosed that he received consulting fees from AbbVie, Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences, Inc., Janssen Pharmaceutica Products, LP, Novartis Pharmaceuticals Corporation, Adaptive Biotechnologies Corporation, Genentech, Inc./Roche Laboratories, Inc., and Pharmacyclics; is a scientific advisor for AbbVie, Inc., AstraZeneca Pharmaceuticals LP, and MorphoSys AG; and receives grant/research support from BeiGene, Gilead Sciences, Inc., MEI Pharma Inc., and Roche Laboratories, Inc. Dr. Baljevic has disclosed that he is a scientific advisor for Karyopharm Therapeutics and Takeda Pharmaceuticals North America, Inc., and receives consulting fees from Cardinal Health and Takeda Pharmaceuticals North America, Inc. Dr. Castillo has disclosed that he receives grant/research support and consulting fees from BeiGene, Janssen Pharmaceutical Products, LP, and Pharmacyclics; and that he receives grant/research support from AbbVie, Inc., and TG Therapeutics, Inc. Dr. Liedtke has disclosed that she receives grant/research support from Agios, Inc., Amgen Inc., Celator Pharmaceuticals, Genentech, Inc., Gilead Sciences, Inc., Janssen Pharmaceutica Products, LP, bluebird bio, Inc., Prothena, Pfizer Inc., and Takeda Pharmaceuticals North America, Inc; receives consulting fees from Amgen Inc.; and is a scientific advisor for Celgene Corporation, Janssen Pharmaceutica Products, LP, and Jazz Pharmaceuticals Inc.
© 2019-2024 National Comprehensive Cancer Network